MK-8591A

DRUG4 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

HIV infectionHIV-1 InfectionHealthy

Phase 1

A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)

CompletedNCT06719570

Merck Sharp & Dohme LLCHealthy

Start: 2024-01-23End: 2024-03-15Updated: 2024-12-06

Phase 3

Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

Active, not recruitingNCT04776252

Merck Sharp & Dohme LLCHIV-1 Infection

Start: 2021-09-15End: 2029-05-29Target: 2000Updated: 2025-12-23

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants

Active, not recruitingCTIS2022-502099-22-01

Merck Sharp & Dohme LLCHIV-1 Infection

Start: 2024-04-29Target: 82Updated: 2025-08-22

A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical Study

Active, not recruitingCTIS2024-512215-53-00

Merck Sharp & Dohme LLCHIV infection

Start: 2021-10-27Target: 84Updated: 2025-11-14